Mahidol University has introduced Chimeric antigen receptor (CAR) modified T-cell therapy to treat B-cell leukaemia, making Thailand the first in the Asean to adopt this cutting-edge technique.
Dr Banjong Mahaisawariya, president of Mahidol University, said the university's ability to roll out a therapy currently used in the treatment of certain blood cancers was the result of a policy to promote integration between departments.
CAR therapy is among the few available options for sufferers of B-cell leukaemia which is often more resistant to chemotherapy than other forms of cancer. It is hoped that domestic development will exponentially ease the financial burden of treatment as it is expensive to import from overseas, he said.
